As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Bioforce Nanosciences Holdings, Inc. The largest reported stake is Nexus Capital Investments, Inc.'s, at 79.6%. One filing is on record since September 4, 2026 (Schedule 13D, September 4, 2026).
Sell to companies like Bioforce Nanosciences Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Nexus Capital Investments, Inc. · Sole voting: 26,700,000 · Shared voting: 26,700,000 · Sole dispositive: 26,700,000 · Shared dispositive: 26,700,000 · SCHEDULE 13D, 2026-09-04
- · Holder: Nexus Capital Investments, Inc. · Percent: 79.6% · SCHEDULE 13D
- · Holder: Nexus Capital Investments, Inc. · Percent: 79.6% · Shares: 26,700,000 · SCHEDULE 13D
Bioforce Nanosciences Holdings, Inc. has 1 Schedule 13D or 13G filing on record since 2026-09-04. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Nexus Capital Investments, Inc. | 79.6% | 26,700,000 | SCHEDULE 13D, 2026-09-04 | 2026-04-22 |
Holding shares or following this stake? See who's behind Bioforce Nanosciences Holdings, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Bioforce Nanosciences Holdings, Inc. and the records around it.
Bioforce Nanosciences Holdings, Inc. elsewhere on the record
- Leadership changes Jun 2026
Watch Bioforce Nanosciences Holdings, Inc.
Get an email when Bioforce Nanosciences Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bioforce Nanosciences Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Bioforce Nanosciences Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bioforce Nanosciences Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Nexus Capital Investments, Inc. | 26,700,000 | 26,700,000 | 26,700,000 | 26,700,000 | SCHEDULE 13D, 2026-09-04 |
The latest filing identifies Bioforce Nanosciences Holdings, Inc. by CUSIP 09064C206 and gives its principal executive office as 2020 GENERAL BOOTH BLVD, SUITE 230, VIRGINIA BEACH, VA 23454 (SCHEDULE 13D, 2026-09-04).
Source of funds (Item 3)
The Reporting entity acquired the 26,700,000 shares of common stock of BFNH in a private transaction for the purchase price of $400,000, and such funds were obtained through operational working capital.Nexus Capital Investments, Inc., SCHEDULE 13D, 2026-09-04
Purpose of Transaction (Item 4)
Nexus Capital Investments, Inc.
(a) N/A (b) BFNH and the Reporting Entity reserve the right to engage in the acquisition of other entities in the form of a merger or acquisition in the future; (c) BFNH and the Reporting Entity reserve the right to engage in the sale or transfer of a material amount of assets in the future; (d) No changes are forthcoming but the Conpany the reserves the right to change the management, the board and their terms in the future; (e) BFNH reserves the right to change the capital structure of the Company in the future. (f) N/A (g)N/A (h)N/A (i) N/A (jj) N/AItem 4 of the SCHEDULE 13D filed 2026-09-04
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-09-04 | Nexus Capital Investments, Inc. | 79.6% | SCHEDULE 13D |
Also on the record for Bioforce Nanosciences Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 18, 2026 | Leadership change: Scott Mager appointed, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Bioforce Nanosciences Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.